Volume 41, Issue 13 pp. 1701-1708
ORIGINAL ARTICLE

Identification of fetal aneuploidy with dual-probe fluorescence in situ hybridization analysis in circulating trophoblasts after enrichment using a high-sensitivity microfluidic platform

Jiri Sonek

Corresponding Author

Jiri Sonek

Department of Obstetrics and Gynecology, Wright State University, Dayton, Ohio, USA

Correspondence

Jiri Sonek, Department of Obstetrics and Gynecology, Wright State University, Berry Pavilion, 1 Wyoming St, Dayton, OH 45409 USA.

Email: [email protected]

Search for more papers by this author
Rolf Muller

Rolf Muller

BioFluidica, Inc., San Diego, California, USA

Search for more papers by this author
Judy Muller-Cohn

Judy Muller-Cohn

BioFluidica, Inc., San Diego, California, USA

Search for more papers by this author
Janet Dickerson

Janet Dickerson

BioFluidica, Inc., San Diego, California, USA

Search for more papers by this author
Brenda Garcia Lopez

Brenda Garcia Lopez

BioFluidica, Inc., San Diego, California, USA

Search for more papers by this author
Jennifer Barber-Singh

Jennifer Barber-Singh

BioFluidica, Inc., San Diego, California, USA

Search for more papers by this author
Dylan Dufek

Dylan Dufek

BioFluidica, Inc., San Diego, California, USA

Search for more papers by this author
Adam Kinney Hiett

Adam Kinney Hiett

Department of Obstetrics and Gynecology, Wright State University, Dayton, Ohio, USA

Search for more papers by this author
Philip Buchanan

Philip Buchanan

Department of Obstetrics and Gynecology, The George Washington University, Washington, DC, USA

Search for more papers by this author
First published: 28 September 2021
Citations: 1

Abstract

Objective

To evaluate a microfluidics-based positive selection technology for isolating circulating trophoblasts (CTs) from peripheral blood of women whose pregnancies are affected by aneuploidy and to evaluate fetal karyotype using fluorescence in situ hybridization (FISH).

Method

Ten 18-ml samples of peripheral blood were collected consecutively from pregnant women whose fetus was affected by aneuploidy. A preservation buffer was added, and the specimens were shipped overnight to the testing laboratory at ambient temperature. The specimen was infused into the fully automated microfluidics-based LiquidScan® instrument without pre-processing. This instrument contains microfluidic chips, which are coated with antibodies (anti-huEpCAM and a proprietary antibody mixture) specific to CT surface epitopes. FISH analysis was performed on the enriched cells.

Results

Fetal aneuploidy evaluated included trisomy 21 (n = 3), trisomy 18 (n = 1), trisomy 13 (n = 1), monosomy X (n = 3), and triploidy (n = 1). CTs for analysis by FISH were identified in all samples. The average number of mononucleate cells per 1 ml of whole blood was 2.11 (range 0.38–4.63) overall and was 2.67 (range 1.13–4.63) using the proprietary combination of antibodies. FISH results were concordant with the aneuploidy based on other testing in all cases. Multinucleate cells were searched for and identified in the last seven samples (average number: 0.84/1 ml).

Conclusions

Our study demonstrates that the LiquidScan®, a high-sensitivity microfluidic platform, can enrich circulating trophoblasts (mononucleate and multinucleate). FISH can then be used to detect fetal aneuploidy.

CONFLICT OF INTEREST

Jiri Sonek, MD, is a Member of the BioFluidica Scientific Advisory Board, Inc., San Diego, California, USA.

Rolf Muller, Ph.D., Judy Muller-Cohn, Ph.D., Janet Dickerson, Brenda Garcia Lopez, Jennifer Barber-Singh, Ph.D., and Dylan Dufek all work for BioFluidica, Inc., San Diego, California, USA.

Philip Buchanan, PhD, is a Member of the Board of Directors of BioFluidica, Inc., San Diego, California, USA.

DATA AVAILABILITY STATEMENT

Data are available upon request.